First Company In China To Receive Regulatory Approval For An Entire IVF Culture Media Portfolio

Vitrolife (STO:VITR) is the first company to receive regulatory approval for an entire IVF culture media portfolio in China. With the approval from Chinese SFDA (State Food and Drug Administration), Vitrolife can now provide a unique level of compliance to the IVF community with products covering all steps of an IVF treatment.

"It has been a long and intense journey to secure that our customers can work with ease of mind, fulfilling regulatory requirements". We are very proud and happy to be the first company to offer approved quality leading products from retrieval to transfer", says Dr. Meishan Jin, Vitrolife's Regional Manager Asia
This approval confirms that Vitrolife brings safe, efficient and certified products in the hands of IVF professionals.

"China experiences very rapid growth in terms of IVF treatments and Vitrolife are one of the companies best positioned to take care of that growth. With this approval, our growth will be further leveraged for the future, says Dr. Magnus Nilsson, CEO Vitrolife"

During the approval process the company has cooperated closely with national authorities, to set the quality standard for IVF-products and secure that customers can work according to Chinese rules and regulations.

The SFDA approval adds to the list of stringent regulatory approvals of Vitrolife products for CE-mark, FDA, Canada Health, TGA accompanied by many local registrations.